Skip to content

Homoeopathic Treatment of Atopic Dermatitis (A Chronic Allergic Skin Disease).

Efficacy of individualized Homoeopathic medicines in Q-potency in the Treatment of Atopic Dermatitis: A double- blind, randomised, placebo-controlled trial.

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/07/043682
Enrollment
60
Registered
2022-07-04
Start date
Unknown
Completion date
Unknown
Last updated
2022-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L209- Atopic dermatitis, unspecified

Interventions

Intervention1: Individualized Homoeopathic Medicines in Q-Potency: Intervention is planned as administering indicated homoeopathic medicines in Q (50 millisimal) potencies, as decided appropriate to t
repeatation depending up on the individual requirement of the case . patients are advised to refrain from taking tea, coffee, alcoholic beverages like whisky, brandy etc, and wearing woolen undergarm
repeatation depending up on the i

Sponsors

The Calcutta Homoeopathic Medical College and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Newly diagnosed cases of AD (ICD-10-CM code L20.9) as per UK diagnostic Criteria, 2. PO-SCORAD more than 10, 3. Patients of 18 - 65 years of age and of either sex, 4. Literate patients; ability to read Bengali and/or English, 5. Patients giving written consent to participate in the trial, 6. Patients already undergoing treatment for AD were planned to be recruited on completely stopping the medicines and after wash-out phase of 1 month

Exclusion criteria

Exclusion criteria: 1.Uncontrolled or life threating illness, any organ failure and other co-morbidities, 2. Patients who are too sick for consultation, 3. Substance abuse and/or dependence, 4. Pregnant and lactating women, 5. Psychiatric illness, 6. Patients undergoing homoeopathic treatment for any chronic disease within last 6 months,

Design outcomes

Primary

MeasureTime frame
PO-SCORAD (Patient oriented scoring Atopic Dermatitis)Index to create a consensus on assessment method for Atopic DermatitisTimepoint: At baseline, 3 months, and 6 months

Secondary

MeasureTime frame
Dermatology Life Quality IndexTimepoint: At baseline, after 3 months and 6 months

Countries

India

Contacts

Public ContactDr Rupali Bhaduri

The Calcutta Homoeopathic Medical College and Hospital

drrupalibhaduri@gmail.com9571806989

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026